Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03692897 · ClinicalTrials.gov registry record
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
A clinical trial, sponsored by Target PharmaSolutions.
- Terminated
- Registry status
- 1,708
- Enrollment target
NCT03692897 is a clinical trial that was terminated before completion, run by Target PharmaSolutions. The registered enrollment target is 1,708 participants.
The verdict
NCT03692897 was terminated before completion, sponsored by Target PharmaSolutions.
- TERMINATED
- Registry status
- 1,708 participants
- Enrollment target
Study Summary
The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical questions regarding the management of CHB by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to antiviral treatments used in clinical practice.
Interventions
- OTHER All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,708 participants |
| Start Date | 2018-10-11 |
| Est. Completion | 2025-09-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03692897
The ClinicalTrials.gov registry entry for NCT03692897 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1,708 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Target PharmaSolutions, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which All approved therapies for the treatment of Chronic Hepatitis B (CHB) is the first listed.
NCT03692897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03692897 about?
NCT03692897 is a clinical study titled "An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection". The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) d...
What is the current status of trial NCT03692897?
This trial is currently terminated. The enrollment target is 1,708 participants. The study started on 2018-10-11. Estimated completion is 2025-09-10.
What interventions are being tested in trial NCT03692897?
The interventions under investigation include: All approved therapies for the treatment of Chronic Hepatitis B (CHB) (OTHER).
Who is sponsoring clinical trial NCT03692897?
This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.